<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:03:04Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/18347" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/18347</identifier><datestamp>2026-10-18T20:56:31Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Cognitive Impairment in Alzheimer’s Disease: Targeting the  Histaminergic System</dc:title><dc:creator>Hacimuftuoglu, Ahmet</dc:creator><dc:creator>ÇIÇEK, BETÜL</dc:creator><dc:creator>AKPINAR, Erol</dc:creator><dc:subject>Nörolojik Bilimler</dc:subject><dc:subject>Farmakoloji ve Eczacılık</dc:subject><dc:description>Alzheimer’s disease is a neurodegenerative disease character ized by a progressive decline in cognitive functions and in the  ability to continue activities of daily living. The exact causes of  Alzheimer’s disease are yet unknown, but researchers suggest  that the formation and aggregation of β-amyloid and phos phorylated tau plaques are among the well-known factors that  explain the pathophysiogenesis of the disease. The mechanisms  by which β-amyloid leads to cognitive decline in Alzheimer’s  disease are associated with degeneration in both cholinergic  and glutamatergic neurotransmission. However, it is proposed  that different neurotransmitter systems with neuronal hista mine also participate in the progress and continuance of cog nitive deficits associated with Alzheimer’s disease. Histamine  serves as a neurotransmitter in brain. Histamine-containing  neurons in the brain are concentrated mainly in tuberomammil lary nucleus located posterior to the hypothalamus and project  widely to the regions such as the cerebellum and hippocampus  that are related to memory and cognitive functions. The cog nitive function modulated by histamine is thanks to the effect  of 4 metabotropic receptors: H1, H2, H3, and H4. Pathological  changes in histamine level and histamine receptor expression  in patients with Alzheimer’s disease are largely predictive of  ensuing cognitive deficits. The review gives a synopsis of the  functions of histaminergic neurotransmission in Alzheimer’s  disease-related cognitive decline, as well as the effects of H1,  H2, H3, and H4 on animal and clinical researches.</dc:description><dc:date>2022</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/18347</dc:identifier><dc:identifier>https://doi.org/10.54614/abcr.2021.21021</dc:identifier><dc:identifier>2687-4520</dc:identifier><dc:language>en</dc:language><dc:relation>Archives of Basic and Clinical Research</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/18347</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>